Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. Review uri icon

Overview

abstract

  • In the 21st century, there has been a dramatic shift in the management of advanced-stage lung carcinoma, and this has coincided with an increasing use of minimally invasive tissue acquisition methods. Both have had significant downstream effects on cytology and small biopsy specimens. Current treatments require morphologic, immunohistochemical, and/or genotypical subtyping of non-small cell lung carcinoma. To meet these objectives, standardized classification of cytology and small specimen diagnoses, immunohistochemical algorithms, and predictive biomarker testing guidelines have been developed. This review provides an overview of current classification, biomarker testing, methods of small specimen acquisition and triage, clinical management strategies, and emerging technologies.

publication date

  • May 28, 2020

Research

keywords

  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Neuroendocrine Tumors
  • Precision Medicine
  • Triage

Identity

Scopus Document Identifier

  • 85086864297

Digital Object Identifier (DOI)

  • 10.1016/j.jasc.2020.04.014

PubMed ID

  • 32591241

Additional Document Info

volume

  • 9

issue

  • 5